




# BMJ Open Epidemiological trends in opioid-only and opioid/polysubstance-related death rates among American Indian/Alaska Native populations from 1999 to 2019: a retrospective longitudinal ecological study

Fares Qeadan <sup>1</sup>, Erin F Madden,<sup>2</sup> Nana A Mensah,<sup>3</sup> Benjamin Tingey <sup>1</sup>, Jalene Herron <sup>4</sup>, Alexandra Hernandez-Vallant,<sup>4</sup> Kamilla L Venner,<sup>4</sup> Kevin English,<sup>5</sup> Amruta Dixit<sup>5</sup>

**To cite:** Qeadan F, Madden EF, Mensah NA, *et al*. Epidemiological trends in opioid-only and opioid/polysubstance-related death rates among American Indian/Alaska Native populations from 1999 to 2019: a retrospective longitudinal ecological study. *BMJ Open* 2022;**12**:e053686. doi:10.1136/bmjopen-2021-053686

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2021-053686>).

Received 09 June 2021  
Accepted 04 March 2022



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

## Correspondence to

Dr Fares Qeadan;  
fqeadan@luc.edu

## ABSTRACT

**Objectives** The rate of drug overdose deaths in the USA has more than tripled since the turn of the century, and rates are disproportionately high among the American Indian/Alaska Native (AI/AN) population. Little is known about the overall historical trends in AI/AN opioid-only and opioid/polysubstance-related mortality. This study will address this gap.

**Design** This is a retrospective longitudinal ecological study.

**Setting** US death records from 1999 to 2019 using the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research.

**Participants** US non-Hispanic AI/AN people age 12 years and older.

**Measures** The primary outcomes, identified via the 10th revision of the International Statistical Classification of Diseases and Related Health Problems codes, included overdose deaths due to (1) opioids only, opioids in combination with any other substance, all-opioid related overdoses; (2) combinations of opioids and alcohol, opioids and methamphetamine, opioids and cocaine, opioids and benzodiazepines; and (3) specific types of opioids.

**Results** From 1999 to 2019, opioid-only mortality rates increased from 2.8 to 15.8 per 100 000 ( $p<0.001$ ) for AI/AN women and 4.6 to 25.6 per 100 000 ( $p<0.001$ ) for AI/AN men. All opioid-related mortality rates increased significantly ( $p<0.001$ ) from 5.2 to 33.9 per 100 000 AI/AN persons, 3.9 to 26.1 for women and 6.5 to 42.1 for men. AI/AN also exhibited significant increases in mortality rates due to opioids and alcohol, opioids and benzodiazepines, opioids and methamphetamine, and AI/AN men experienced substantial increases in mortality due to opioids and cocaine. Mortality rates by individual opioid types increased significantly over time for heroin, natural and semi-synthetic (prescription), and synthetic opioids (fentanyl/fentanyl analogues) other than methadone.

**Conclusions** These findings highlight magnification over time in opioid-related deaths and may point to broader

## Strengths and limitations of this study

- This is one of the first studies to consider the historical trends of opioid overdose mortality in the American Indian/Alaska Native (AI/AN) population across the USA, with particular attention given to how co-use of opioids with certain substances contributes to drug overdose mortality in this population.
- This study offers stratified results by sex and compares mortality rates between non-Hispanic AI/AN populations and other race/ethnicity groups to better identify subpopulations at risk of overdose death.
- This study provides insight into trends about opioid overdose mortality in the AI/AN population by specific opioid types, which can help guide harm reduction and public health prevention efforts for AI/AN communities.
- Due to data-use agreement requirements, subgroup data with small counts could not be disaggregated.
- Age-adjusted rates could not be obtained because they require larger sample sizes to avoid data suppression for small sample sizes.

systemic factors that may disproportionately affect members of AI/AN communities and drive inequities.

## INTRODUCTION

Over the past two decades, the rate of drug overdose deaths in the USA has more than tripled.<sup>1</sup> This spike in overdoses, described as a public health crisis, has grown more destructive with time.<sup>1 2</sup> The American Indian/Alaska Native (AI/AN) population has been disproportionately affected by drug-related mortality. From 1999 to 2015, drug overdose mortality among metropolitan AI/AN populations increased from 7.1 per 100 000 to 22.1

per 100 000, representing a 261% change from 1999.<sup>3</sup> A magnified pattern was observed in non-metro AI/AN populations, whose overdose mortality rate climbed steeply from 3.9 per 100 000 in 1999 to 19.8 per 100 000 in 2015, representing a 519% increase.<sup>3</sup> Other groups also experienced rises in drug overdoses over this same period but at lower rates of change.<sup>3</sup>

Opioid overdose fatalities among AI/AN and non-Hispanic White populations both rose dramatically since 1999, surpassing national rates in all years since 2002.<sup>4</sup> While non-Hispanic White populations exhibit the highest rates since 2014, AI/AN populations demonstrate the second highest opioid overdose mortality across US racial and ethnic groups. In 1999, the AI/AN opioid overdose mortality rate was 2.9 per 100 000 and had risen to 17.0 deaths per 100 000 by 2019.<sup>4</sup> Regional variations also exist in this trend among AI/AN populations. From 1999 to 2016, higher mortality rates from opioids among AI/AN were observed in states in the Pacific Northwest, and Great Lakes Region.<sup>5</sup> During 2013–2015, mortality rates among AI/AN populations in Washington state were 2.7 higher than rates among non-Hispanic White populations for all opioid-involved overdoses.<sup>6</sup>

The literature also points to variations in overdose rates from specific opioid types. Increases in overdose due to synthetic opioids, primarily driven by illicitly manufactured fentanyl, have contributed to the bulk of US opioid-involved fatalities in recent years.<sup>7,8</sup> From 2017 to 2018, overdose death rates from synthetic opioids other than methadone among AI/AN populations increased from 6.5 per 100 000 to 7.3 per 100 000 deaths.<sup>9</sup> Compared with non-Hispanic Whites and non-Hispanic Blacks, AI/AN overdose rates from synthetic opioids were lower, but AI/AN rates were higher than Hispanic and Pacific Islander rates.<sup>9</sup> Additionally, while the USA has seen recent declines in heroin overdoses, decreases observed among AI/AN populations are modest compared with other racial and ethnic populations.<sup>9</sup>

Regarding polysubstance use, the literature suggests that people who use opioids often use other drugs concurrently, thereby creating drug interactions that can increase overdose risk.<sup>10</sup> The co-use of opioids with some other drugs may be of particular concern for AI/AN populations, as treatment admission data from the Treatment Episode Data Set demonstrated that among US racial groups, AI/AN respondents consistently reported the highest rates of individuals entering treatment with concurrent use of methamphetamine and heroin each year from 2008 to 2017.<sup>11</sup>

The reasons for higher rates of drug overdose among Indigenous people are many but likely originate from a persistent legacy of colonialism, racism and intergenerational trauma.<sup>12,13</sup> This legacy is often complicated by current social, economic, and health disadvantages experienced by many AI/AN populations.<sup>12–14</sup> Taken together, these circumstances provide the ideal for increased risk of overdose.<sup>12,15</sup>

Although previous reports show AI/AN populations across the USA have experienced elevated rates of drug overdose deaths, the significance of historical trends in drug-related death rates among AI/AN populations remains unclear, especially regarding trends in deaths related to polysubstance use, which have risen dramatically in the general US population in recent years. Deaths involving psychostimulants (eg, cocaine, methamphetamine, MDMA and prescription stimulants) increased by over 30% between 2016 and 2017 across the USA, and in 2017, over 70% of cocaine-involved overdose deaths and 50% of other psychostimulant-involved overdose deaths involved at least one opioid.<sup>16</sup> This study provides foundational knowledge on overdose deaths involving opioids among AI/AN populations by analysing the historical patterns of opioid-only and opioid/polysubstance-related deaths.

## METHODS

### Settings

This is a retrospective longitudinal ecological study that uses serial cross-sectional data to analyse historical patterns of opioid-only and polysubstance-involved opioid overdose deaths among AI/AN populations. Specifically, this retrospective observational study used publicly available data from the Centers for Disease Control and Prevention (CDC) Wide-Ranging Online Data for Epidemiologic Research (WONDER) database. Data on drug overdose deaths due to opioids and combinations of opioids with either alcohol, benzodiazepines, cocaine or methamphetamine were obtained from the CDC WONDER's National Center for Health Statistics Mortality database (NCHS). This database contains county-level data comprising both mortality and population counts across all 50 United States and the District of Columbia. Mortality data were captured by either (1) being coded by states and provided to NCHS per the Vital Statistics Cooperative Programme or (2) state registration offices providing copies of physical death certificates to the NCHS to be coded by the NCHS itself. Mortality information from individuals classified as non-residents (ie, non-resident aliens, citizens living abroad, residents of Puerto Rico, Guam, the Virgin Islands, other territories of the USA) as well as fetal deaths were excluded from capture. Population data were captured from the US Census Bureau and comprise mid-year census, estimates of national, state and county resident populations. Additional information such as time and place of death, place of residence, age, sex, race and ethnicity are also provided with the demographic data being captured on the death certificate for mortality data and by self-reporting for population data. The data spanned from 1999 to 2019, included all USA, all urbanisation categories, all weekdays, all autopsy values and all place of death categories. The population of interest was US non-Hispanic (NH) AI/AN of the age of 12 and older.

### Measures

All deaths were identified from the NCHS Mortality database by the underlying cause of death and multiple

causes of death with the International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10) codes. The outcomes of interest were separated into three scenarios: (1) overdose deaths relating to opioids alone (opioid-only), opioids in combination with any other substances (opioid/polysubstance), the sum of opioid-only and opioid/polysubstance cases (all-opioid related); (2) overdose deaths relating to opioids in combination with each of the other substance types and (3) overdose deaths separated by individual opioid types (heroin, natural and semi-synthetic (prescription) opioids (eg, oxycodone, hydrocodone), methadone and synthetic opioids other than methadone (eg, fentanyl, tramadol)). Opium (multiple cause code T40.0) and unknown opioids (T40.6) were not displayed alone because counts were too small. The specific substance-related overdose death types and corresponding ICD-10 codes are displayed by the outcome scenario in [table 1](#). While types of opioids are differentiated by these ICD codes, whether an opioid was prescribed or obtained via unregulated sources is not discernible using these data.

For multiple causes of death codes, any qualifying code from the list of available codes was counted towards the outcome. In the case of opioids in combination with another substance, any qualifying code from the list of available opioid multiple causes of death codes (T40.0, T40.1, T40.2, T40.3, T40.4, T40.6) and any code from the other substance(s) list was counted towards the outcome. The count of deaths was divided by the population of interest and multiplied by 100 000 to provide a mortality rate per 100 000 NH AI/AN 12 years and older. Per the data use agreement of CDC WONDER, all counts 9, and lower were classified as 10. Trend analysis was stratified by age (15–24, 25–34, 35–44, 45+), sex (female, male) and race/ethnicity (NH AI/AN, NH Asian or Pacific Islander (API), NH Black, NH White, Hispanic/Latino). Because age groupings were allowed only in 5-year and 10-year increments, the age group was restricted to those 15 years and older instead of 12 years and older.

### Statistical analysis

Overdose death rates per 100 000 NH AI/AN population 12 and older, relating to the three outcome scenarios, were presented over time from 1999 to 2019. Figures and tables were constructed with 95% exact Poisson confidence intervals (CIs). To assess significant trends over time, non-parametric Jonckheere-Terpstra tests were performed for each substance type because rates exhibited non-normal distributions. All analysis results were presented overall and stratified by sex to identify sex-specific trends in the outcomes of interest. Online supplemental figures IA-B were displayed for mortality rates due to opioids-only and opioids in combination with each other substance. Rates were stratified by age groups as well as by race/ethnicity. Racial comparisons were performed to assess how NH AI/AN rates compared with those of other racial groups.

**Table 1** Substance-related overdose death types, and associated ICD-10 codes, by outcome scenario

	Underlying cause of death ICD-10	Multiple cause of death ICD-10*
<b>Scenario 1</b>		
Opioid-only	X40-44, X60-64, X85, Y10-Y14	T40.0, T40.1, T40.2, T40.3, T40.4, T40.6
Opioid/polysubstance	R78.0, X40-45, X60-65, X85, Y10-Y15	T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 AND T40.5, T42.4, T43.6, T51.0, T51.1, T51.9
All-opioid related†	R78.0, X40-45, X60-65, X85, Y10-Y15	T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 OR (T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 AND T40.5, T42.4, T43.6, T51.0, T51.1, T51.9)
<b>Scenario 2</b>		
Opioids and methamphetamine	X40-44, X60-64, X85, Y10-Y14	T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 AND T43.6
Opioids and cocaine	X40-44, X60-64, X85, Y10-Y14	T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 AND T40.5
Opioids and benzodiazepines	X40-44, X60-64, X85, Y10-Y14	T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 AND T42.4
Opioids and alcohol	R78.0, X40-45, X60-65, X85, Y10-Y15	T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 AND T51.0, T51.1, T51.9
<b>Scenario 3</b>		
Heroin	X40-44, X60-64, X85, Y10-Y14	T40.1
Natural and semi-synthetic (prescription) opioids	X40-44, X60-64, X85, Y10-Y14	T40.2
Methadone	X40-44, X60-64, X85, Y10-Y14	T40.3
Synthetic opioids (other than methadone)	X40-44, X60-64, X85, Y10-Y14	T40.4

\*Any of prescribed codes, if an 'AND' is included then at least one from first code group AND one from other code group.

†Sum of opioid-only and opioid/polysubstance.

ICD-10, International Statistical Classification of Diseases and Related Health Problems, 10th Revision.

All hypothesis tests were two-sided with a significance level of 5%. R V.3.6.1 (R Foundation for Statistical Computing) was used to perform all analyses.


### Patient and public involvement

No patient was involved.

### RESULTS

From 1999 to 2019 ([figure 1](#), [table 2](#)), NH AI/AN opioid mortality rates increased significantly (all  $p < 0.001$ ) overall and for both women and men. All opioid-related





**Figure 1** Trends in opioid death rates among US non-Hispanic American Indian/Alaska Native 12 and older by opioid-only (no other substances), opioid/polysubstance (opioids and at least one other substance) and all opioid-related cases (sum of opioid-only and opioid/polysubstance). Opioid-only (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6); opioid/polysubstance (underlying: R78.0, X40-45, X60-65, X85, Y10-Y15; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T40.5, T42.4, T43.6, T51.0, T51.1, T51.9); all-opioid related: sum of 'opioid-only' and 'opioid/polysubstance'.

mortality rates increased from 5.2 to 33.9 per 100 000 overall, 3.9 to 26.1 per 100 000 women and 6.5 to 42.1 per 100 000 men. Opioid-only rates increased from 3.7 to 20.6 per 100 000 overall, 2.8 to 15.8 per 100 000 women, and 4.6 to 25.6 per 100 000 men. Opioid/polysubstance rates increased from 1.5 to 13.3 per 100 000 overall, 1.1 to 10.3 per 100 000 women, and 1.9 to 16.5 per 100 000 men. Rates increased significantly even with total population counts of NH AI/AN increasing across 1999–2019 from 1 764 431 to 2 285 417 overall, from 902 815 to 1 173 309 for males, and from 861 616 to 1 112 108 for females.

Significant trends were also observed for mortality due to opioids in combination with other specific substances, with the exception of opioids and cocaine overall and among women (figure 2, table 3). Significantly increasing mortality rates were seen overall in NH AI/AN due to opioids and alcohol (rates per 100 000: 1.1 to 4.2,  $p<0.001$ ), opioids and benzodiazepines (rates per 100 000: 1.1 to 2.6,  $p<0.001$ ), and opioids and methamphetamine (rates per 100 000: 0.6 to 6.7,  $p=0.001$ ). By sex, NH AI/AN men and women both exhibited significant increases in mortality rates due to opioids and alcohol (rates per 100 000 women: 1.1 to 2.1,  $p=0.01$ ; rates per 100 000 men: 1.2 to 6.5,  $p<0.001$ ), opioids and benzodiazepines (rates per 100 000 women: 1.1 to 2.0,  $p=0.01$ ; rates per 100 000 men: 1.2 to 3.1,  $p<0.001$ ), and opioids and methamphetamine (rates per 100 000 women: 1.1 to 6.2,  $p=0.02$ ; rates per 100 000 men: 1.2 to 7.1,  $p=0.02$ ). Only NH AI/AN men exhibited significantly increasing mortality rates due

to opioids and cocaine (rates per 100 000 men: 1.2 to 3.2,  $p=0.02$ ).

When looking deeper into individual opioid types (figure 3, table 4) there was a significant rise in natural and semi-synthetic (prescription) opioid death rates (rates per 100 000 overall: 1.4 to 5.1,  $p<0.001$ ; rates per 100 000 women: 1.1 to 4.8,  $p<0.001$ ; rates per 100 000 men: 1.6 to 5.4,  $p<0.001$ ) and heroin (rates per 100 000 overall: 1.2 to 6.3,  $p<0.001$ ; rates per 100 000 women: 1.1 to 4.9,  $p=0.056$  (on the boundary of significance); rates per 100 000 men 1.3 to 7.7,  $p<0.001$ ). Death rates due to synthetic opioids (other than methadone) saw a drastic increase in recent years (2013–2019 rates per 100 000 overall: 1.5 to 12.5,  $p<0.001$ ; 2013–2019 rates per 100 000 women: 1.5 to 8.6,  $p<0.001$ ; 2013–2019 rates per 100 000 men: 1.5 to 16.5,  $p<0.001$ ).

Supplemental analyses, by age groups, revealed that NH AI/AN ages 25–44 had higher opioid-only and opioid-combination mortality rates than those 15–24 and older than 44 (online supplemental figure 1A). Overall and across both sexes, NH AI/AN populations generally exhibited opioid-only and opioid-combination mortality rates as high or higher than other races. Death rates across all years relating to opioids and methamphetamine remained consistently higher for NH AI/AN compared with all other races. However, in more recent years, NH White rates exceeded those of the NH AI/AN population, as seen in opioid-only and opioid-benzodiazepine mortality rates. NH Black men, additionally, saw higher

**Table 2** Trends in opioid death rates per 100 000 (95% CI) among US non-Hispanic American Indian/Alaska Native 12 and older by opioid-only (no other substances), opioid/polysubstance (opioids and at least one other substance) and all opioid-related cases (sum of opioid-only and opioid/polysubstance)


	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	Trend p value*
<b>Overall</b>																						
All opioid-related	5.2 (4.2 to 6.3)	5.0 (4.1 to 6.1)	5.7 (4.6 to 6.8)	6.8 (5.7 to 8.0)	8.6 (7.3 to 10.0)	10.6 (8.7 to 11.5)	12.0 (10.5 to 13.5)	11.5 (10.0 to 13.0)	14.1 (12.5 to 15.8)	16.0 (14.3 to 17.8)	19.8 (17.9 to 21.7)	17.3 (15.5 to 19.1)	18.0 (16.2 to 19.9)	20.0 (18.2 to 22.0)	18.5 (16.8 to 20.4)	21.5 (19.6 to 23.4)	22.2 (20.3 to 24.2)	25.6 (23.5 to 27.7)	28.6 (26.4 to 30.9)	25.8 (23.8 to 28.0)	33.9 (31.5 to 36.3)	<0.001
Opioid-only	3.7 (2.8 to 4.6)	3.3 (2.5 to 4.2)	4.2 (3.3 to 5.2)	5.1 (4.1 to 6.1)	6.4 (5.3 to 7.5)	7.5 (6.3 to 8.8)	8.2 (7.0 to 9.5)	9.7 (8.3 to 11.0)	9.6 (8.3 to 10.9)	11.3 (9.9 to 12.9)	13.5 (12.0 to 15.2)	11.4 (10.0 to 12.9)	12.2 (10.8 to 13.8)	13.2 (11.7 to 14.8)	12.7 (11.2 to 14.2)	14.2 (12.6 to 15.8)	14.3 (12.7 to 15.9)	16.6 (15.0 to 18.3)	18.2 (16.5 to 20.0)	16.5 (14.8 to 18.2)	20.6 (18.7 to 22.5)	<0.001
Opioid/polysubstance	1.5 (1.0 to 2.1)	1.7 (1.2 to 2.3)	1.5 (1.0 to 2.1)	1.7 (1.2 to 2.3)	2.2 (1.6 to 3.0)	2.5 (1.9 to 3.3)	3.8 (2.9 to 4.7)	3.1 (2.3 to 3.9)	4.5 (3.6 to 5.5)	4.7 (3.8 to 5.6)	6.2 (5.2 to 7.4)	5.9 (4.9 to 6.9)	5.8 (4.8 to 6.8)	6.8 (5.8 to 8.0)	5.9 (4.9 to 6.9)	7.3 (6.2 to 8.5)	8.0 (6.8 to 9.2)	9.0 (7.8 to 10.2)	10.4 (9.1 to 11.8)	9.4 (8.1 to 10.7)	13.3 (11.8 to 14.8)	<0.001
Population count	1764431	1830341	1857916	1888990	1917057	1946151	1972126	1996129	2016480	2036583	2054468	2067226	2099967	2126296	2151271	2176524	2199588	2222736	2243570	2265155	2285417	
<b>Female</b>																						
All opioid-related	3.9 (2.7 to 5.3)	3.6 (2.5 to 5.0)	5.2 (3.8 to 6.7)	4.9 (3.6 to 6.4)	6.4 (4.9 to 8.1)	6.8 (5.3 to 8.5)	9.6 (7.8 to 11.6)	7.6 (6.0 to 9.4)	12.9 (10.8 to 15.2)	11.3 (9.4 to 13.4)	13.1 (11.1 to 15.4)	15.0 (12.8 to 17.4)	15.7 (13.4 to 18.1)	16.8 (14.4 to 19.3)	16.7 (14.4 to 19.2)	15.3 (13.1 to 17.7)	16.7 (14.4 to 19.1)	21.0 (18.4 to 23.7)	22.1 (19.4 to 24.9)	18.5 (16.1 to 21.0)	26.1 (23.2 to 29.1)	<0.001
Opioid-only	2.8 (1.8 to 4.0)	2.2 (1.4 to 3.3)	3.9 (2.7 to 5.2)	3.8 (2.7 to 5.2)	5.1 (3.8 to 6.6)	5.2 (3.9 to 6.7)	6.8 (5.3 to 8.5)	5.9 (4.5 to 7.4)	9.0 (7.3 to 10.9)	8.6 (6.9 to 10.5)	9.1 (7.4 to 11)	10.6 (8.7 to 12.6)	11.7 (9.8 to 13.9)	11.9 (9.9 to 14)	10.5 (8.7 to 12.5)	11.0 (9.1 to 13)	13.8 (11.7 to 16)	13.8 (11.8 to 16)	13.8 (11.8 to 16)	12.0 (10.1 to 14)	15.8 (13.6 to 18.1)	<0.001
Opioid/polysubstance	1.1 (0.5 to 1.9)	1.4 (0.7 to 2.2)	1.3 (0.7 to 2.1)	1.0 (0.5 to 1.8)	1.3 (0.7 to 2.1)	1.6 (0.9 to 2.5)	2.8 (1.8 to 3.9)	1.8 (1.0 to 2.7)	3.9 (2.8 to 5.2)	2.7 (1.8 to 3.8)	4.0 (2.9 to 5.3)	4.4 (3.3 to 5.8)	5.1 (3.8 to 6.5)	5.0 (3.8 to 6.5)	4.8 (3.6 to 6.2)	6.2 (4.8 to 7.1)	5.7 (4.4 to 7.1)	7.2 (5.7 to 8.8)	8.3 (6.7 to 10.0)	6.5 (5.2 to 8.1)	10.3 (8.6 to 12.2)	<0.001
Population count	902815	935494	949825	965851	980999	995787	1009648	1022161	1033040	1043730	1053484	1060368	1076977	1090386	1102971	1115777	1127409	1139704	1150832	1162585	1173309	
<b>Male</b>																						
All opioid-related	6.5 (4.9 to 8.3)	6.5 (4.9 to 8.3)	6.2 (4.7 to 7.9)	8.8 (7.0 to 10.8)	10.9 (8.9 to 13.1)	13.4 (11.1 to 15.8)	14.4 (12.1 to 16.9)	15.5 (13.1 to 18.1)	15.4 (13.0 to 17.9)	20.9 (18.2 to 23.9)	26.8 (23.7 to 30.1)	19.7 (17.0 to 22.5)	20.4 (17.8 to 23.3)	23.5 (20.6 to 26.5)	20.5 (17.9 to 23.3)	27.9 (24.8 to 31.2)	28.1 (25.0 to 31.3)	30.4 (27.2 to 33.7)	35.5 (32.1 to 39.1)	33.6 (30.2 to 37.1)	42.1 (38.4 to 46.0)	<0.001
Opioid-only	4.6 (3.3 to 6.2)	4.5 (3.2 to 6.0)	4.5 (3.2 to 6.0)	6.4 (4.9 to 8.1)	7.7 (6.0 to 9.6)	9.9 (8.0 to 12)	9.7 (7.8 to 11.7)	11.1 (9.1 to 13.3)	10.2 (8.3 to 12.3)	14.2 (12.0 to 16.6)	18.2 (15.6 to 20.9)	12.3 (10.2 to 14.6)	14.0 (11.8 to 16.4)	14.8 (12.5 to 17.2)	13.5 (11.4 to 15.9)	18.0 (15.5 to 20.6)	17.7 (15.3 to 20.3)	19.6 (17.0 to 22.3)	22.8 (20.0 to 25.7)	21.2 (18.6 to 24.0)	25.6 (22.7 to 28.7)	<0.001
Opioid/polysubstance	1.9 (1.1 to 2.9)	2 (1.2 to 3.0)	1.7 (0.9 to 2.6)	2.4 (1.5 to 3.5)	3.2 (2.2 to 4.4)	3.5 (2.4 to 4.8)	4.8 (3.5 to 6.3)	4.4 (3.2 to 5.8)	5.2 (3.9 to 6.7)	6.7 (5.2 to 8.5)	8.6 (6.9 to 10.5)	7.3 (5.8 to 9.1)	6.5 (5.0 to 8.1)	8.7 (7.0 to 10.6)	7.0 (5.5 to 8.6)	9.9 (8.1 to 11.9)	10.4 (8.5 to 12.4)	10.8 (8.9 to 12.8)	12.7 (10.7 to 14.9)	12.3 (10.3 to 14.5)	16.5 (14.2 to 18.9)	<0.001
Population count	861616	894847	908091	923139	936058	950364	962478	973968	983440	992853	1000984	1006858	1022990	1035910	1048300	1060747	1072179	1083032	1092738	1102570	1112108	

Opioid/polysubstance (underlying: R78.0, X40-45, X69-65, X85, Y10-Y15; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.5, T40.6 and T40.7, T40.8, T40.9, T41.0, T41.1, T41.2, T41.3, T41.4, T41.5, T41.6, T41.7, T41.8, T41.9, T42.0, T42.1, T42.2, T42.3, T42.4, T42.5, T42.6, T42.7, T42.8, T42.9, T43.0, T43.1, T43.2, T43.3, T43.4, T43.5, T43.6, T43.7, T43.8, T43.9, T44.0, T44.1, T44.2, T44.3, T44.4, T44.5, T44.6, T44.7, T44.8, T44.9, T45.0, T45.1, T45.2, T45.3, T45.4, T45.5, T45.6, T45.7, T45.8, T45.9, T46.0, T46.1, T46.2, T46.3, T46.4, T46.5, T46.6, T46.7, T46.8, T46.9, T47.0, T47.1, T47.2, T47.3, T47.4, T47.5, T47.6, T47.7, T47.8, T47.9, T48.0, T48.1, T48.2, T48.3, T48.4, T48.5, T48.6, T48.7, T48.8, T48.9, T49.0, T49.1, T49.2, T49.3, T49.4, T49.5, T49.6, T49.7, T49.8, T49.9, T50.0, T50.1, T50.2, T50.3, T50.4, T50.5, T50.6, T50.7, T50.8, T50.9, T51.0, T51.1, T51.2, T51.3, T51.4, T51.5, T51.6, T51.7, T51.8, T51.9).

All-cause related: sum of opioid-only and opioid/polysubstance.

\*Non-parametric Jonckheere-Terpstra test for trend.

†Opioid-only (underlying: X40-44, X69-64, X85, Y10-Y14; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.5).



**Figure 2** Trends in opioid combination\* death rates among US non-Hispanic American Indian/Alaska Native 12 and older by substance combination type. Opioids and methamphetamine (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T43.6); opioids and cocaine (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T40.5); opioids and benzodiazepines (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T42.4); opioids and alcohol (underlying: R78.0, X40-45, X60-65, X85, Y10-Y15; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T51.0, T51.1, T51.9).

opioid-only mortality rates than NH AI/AN men in recent years. Opioid and cocaine-related death rates among the NH Black population also exceeded rates of the NH AI/AN population overall and for men across most years and more recently for women. NH AI/AN exhibited higher opioid and alcohol mortality than other races, with NH Blacks showing slightly higher rates in recent years (online supplemental figure 2A–E).

## DISCUSSION

This study provides a comprehensive historical overview of fatal drug overdose trends for NH AI/AN populations in the USA, with particular attention to the role of opioids and combinations of opioids with alcohol, benzodiazepines, methamphetamine and cocaine. We found that among NH AI/AN, mortality rates due to opioids have increased significantly over time. The trend of rising opioid-overdose mortality remains when data are stratified by sex and across age categories. Deaths due to polysubstance use involving opioids have also increased significantly over time among NH AI/AN populations. Among specific opioid types, heroin and natural/semi-synthetic (prescription) opioid-related deaths have risen across the years, however, synthetic opioid-related deaths have spiked just in recent years alone. When comparing across US racial and ethnic groups, NH AI/AN populations exhibit rising opioid-overdose mortality rates that have generally been higher than other groups, but in recent

years NH AI/AN men's rates were below those of NH White and NH Black men, and NH AI/AN populations also display lower rates of death related to opioids and cocaine than NH Black populations. However, NH AI/AN populations exhibit higher mortality rates of opioid combinations with methamphetamine and alcohol than all other US racial/ethnic groups.


In general, the increasing opioid overdose mortality from 1999 to 2019 among NH AI/AN populations observed in our analysis mirror the rising opioid overdose trends in the US general population.<sup>19 17</sup> Similarly, deaths resulting from opioid combinations with other drugs among AI/AN populations follow an increasing trend that is supported by prior research.<sup>16</sup> The combination of opioids with other substances can be a potent inducer of drug overdose. Alcohol, opioids (heroin/morphine, tramadol, oxycodone, etc), and benzodiazepines depress the central nervous system when used alone.<sup>18 19</sup> However, the combination of opioids with other substances may generate complex drug interactions associated with a heightened risk of fatal overdose.<sup>10 20</sup> Consequently, our results showed an escalation in mortality due to opioids in combination with methamphetamine and opioids in combination with alcohol from 1999 to 2019. Consistent with our findings, data from the CDC reported that roughly half of all psychostimulant deaths in 2017 also involved an opioid. Additionally, they observed a significant rise in deaths due to

**Table 3** Trends in opioid combination\* death rates per 100 000 (95% CI) among US non-Hispanic American Indian/Alaska Native 12 and older by substance combination type

	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	Trend p value†	
<b>Overall</b>																							
Opioids and alcohol	1.1 (0.7 to 1.7)	1.1 (0.7 to 1.6)	1.1 (0.7 to 1.6)	1.2 (0.7 to 1.7)	1.4 (0.9 to 2.0)	1.4 (0.9 to 2.0)	1.4 (0.9 to 2.0)	1.4 (0.9 to 1.9)	1.5 (1.0 to 2.0)	1.5 (1.0 to 2.0)	1.5 (1.0 to 2.0)	1.5 (1.0 to 2.0)	1.5 (1.0 to 2.0)	1.5 (1.0 to 2.0)	1.5 (1.0 to 2.0)	1.5 (1.0 to 2.0)	1.5 (1.0 to 2.0)	1.5 (1.0 to 2.0)	1.5 (1.0 to 2.0)	1.5 (1.0 to 2.0)	1.5 (1.0 to 2.0)	1.5 (1.0 to 2.0)	<0.001
Opioids and benzodiazepines	1.1 (0.7 to 1.7)	1.1 (0.7 to 1.6)	1.1 (0.7 to 1.6)	1.1 (0.6 to 1.6)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	<0.001
Opioids and cocaine	1.1 (0.7 to 1.7)	1.1 (0.7 to 1.6)	1.1 (0.7 to 1.6)	1.1 (0.6 to 1.6)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	0.14
Opioids and methamphetamine	0.6 (0.3 to 1.0)	-	1.1 (0.7 to 1.6)	0.5 (0.3 to 0.9)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	0.5 (0.2 to 0.8)	0.5 (0.2 to 0.8)	0.5 (0.2 to 0.8)	0.5 (0.2 to 0.8)	0.5 (0.2 to 0.8)	0.5 (0.2 to 0.8)	0.5 (0.2 to 0.8)	0.5 (0.2 to 0.8)	0.5 (0.2 to 0.8)	0.5 (0.2 to 0.8)	0.5 (0.2 to 0.8)	0.5 (0.2 to 0.8)	0.5 (0.2 to 0.8)	0.5 (0.2 to 0.8)	0.001
Population count	1764431	1830341	1857916	1888990	1917057	1946151	1972126	1996129	2016480	2036583	2054468	2067226	2099967	2126296	2151271	2176524	2199588	2222736	2243570	2265155	2285417		
<b>Female</b>																							
Opioids and alcohol	1.1 (0.5 to 1.9)	1.1 (0.5 to 1.8)	1.1 (0.5 to 1.8)	1.0 (0.5 to 1.8)	1.0 (0.5 to 1.7)	1.0 (0.5 to 1.7)	1.0 (0.5 to 1.7)	1.0 (0.5 to 1.7)	1.4 (0.7 to 2.2)	1.4 (0.7 to 2.2)	1.4 (0.7 to 2.2)	1.4 (0.7 to 2.2)	1.4 (0.7 to 2.2)	1.4 (0.7 to 2.2)	1.4 (0.7 to 2.2)	1.4 (0.7 to 2.2)	1.4 (0.7 to 2.2)	1.4 (0.7 to 2.2)	1.4 (0.7 to 2.2)	1.4 (0.7 to 2.2)	1.4 (0.7 to 2.2)	1.4 (0.7 to 2.2)	0.01
Opioids and benzodiazepines	1.1 (0.5 to 1.9)	1.1 (0.5 to 1.8)	1.1 (0.5 to 1.8)	1.0 (0.5 to 1.8)	1.0 (0.5 to 1.7)	1.0 (0.5 to 1.7)	1.0 (0.5 to 1.7)	1.0 (0.5 to 1.7)	1.8 (1.1 to 2.8)	1.8 (1.1 to 2.8)	1.8 (1.1 to 2.8)	1.8 (1.1 to 2.8)	1.8 (1.1 to 2.8)	1.8 (1.1 to 2.8)	1.8 (1.1 to 2.8)	1.8 (1.1 to 2.8)	1.8 (1.1 to 2.8)	1.8 (1.1 to 2.8)	1.8 (1.1 to 2.8)	1.8 (1.1 to 2.8)	1.8 (1.1 to 2.8)	1.8 (1.1 to 2.8)	0.01
Opioids and cocaine	1.1 (0.5 to 1.9)	1.1 (0.5 to 1.8)	1.1 (0.5 to 1.8)	1.0 (0.5 to 1.8)	1.0 (0.5 to 1.7)	1.0 (0.5 to 1.7)	1.0 (0.5 to 1.7)	1.0 (0.5 to 1.7)	1.1 (0.5 to 1.8)	1.1 (0.5 to 1.8)	1.1 (0.5 to 1.8)	1.1 (0.5 to 1.8)	1.1 (0.5 to 1.8)	1.1 (0.5 to 1.8)	1.1 (0.5 to 1.8)	1.1 (0.5 to 1.8)	1.1 (0.5 to 1.8)	1.1 (0.5 to 1.8)	1.1 (0.5 to 1.8)	1.1 (0.5 to 1.8)	1.1 (0.5 to 1.8)	1.1 (0.5 to 1.8)	0.49
Opioids and methamphetamine	-	-	1.1 (0.5 to 1.8)	-	1.0 (0.5 to 1.7)	1.0 (0.5 to 1.7)	1.0 (0.5 to 1.7)	1.0 (0.5 to 1.7)	1.0 (0.5 to 1.7)	1.0 (0.5 to 1.7)	1.0 (0.5 to 1.7)	1.0 (0.5 to 1.7)	1.0 (0.5 to 1.7)	1.0 (0.5 to 1.7)	1.0 (0.5 to 1.7)	1.0 (0.5 to 1.7)	1.0 (0.5 to 1.7)	1.0 (0.5 to 1.7)	1.0 (0.5 to 1.7)	1.0 (0.5 to 1.7)	1.0 (0.5 to 1.7)	1.0 (0.5 to 1.7)	0.02
Population count	902815	935494	949825	965851	980999	995787	1009648	1022161	1033040	1043730	1053484	1060368	1076977	1090386	1102971	1115777	1127409	1139704	1150832	1162585	1173309		
<b>Male</b>																							
Opioids and alcohol	1.2 (0.6 to 2.0)	1.1 (0.5 to 1.9)	1.1 (0.5 to 1.9)	1.3 (0.7 to 2.1)	1.8 (1.1 to 2.8)	1.8 (1.1 to 2.7)	1.8 (1.1 to 2.7)	1.8 (1.1 to 2.7)	1.2 (0.6 to 2.0)	1.2 (0.6 to 2.0)	1.2 (0.6 to 2.0)	1.2 (0.6 to 2.0)	1.2 (0.6 to 2.0)	1.2 (0.6 to 2.0)	1.2 (0.6 to 2.0)	1.2 (0.6 to 2.0)	1.2 (0.6 to 2.0)	1.2 (0.6 to 2.0)	1.2 (0.6 to 2.0)	1.2 (0.6 to 2.0)	1.2 (0.6 to 2.0)	1.2 (0.6 to 2.0)	<0.001
Opioids and benzodiazepines	1.2 (0.6 to 2.0)	1.1 (0.5 to 1.9)	1.1 (0.5 to 1.9)	1.1 (0.5 to 1.9)	1.1 (0.5 to 1.8)	1.1 (0.5 to 1.8)	1.1 (0.5 to 1.8)	1.1 (0.5 to 1.8)	1.6 (0.9 to 2.4)	1.6 (0.9 to 2.4)	1.6 (0.9 to 2.4)	1.6 (0.9 to 2.4)	1.6 (0.9 to 2.4)	1.6 (0.9 to 2.4)	1.6 (0.9 to 2.4)	1.6 (0.9 to 2.4)	1.6 (0.9 to 2.4)	1.6 (0.9 to 2.4)	1.6 (0.9 to 2.4)	1.6 (0.9 to 2.4)	1.6 (0.9 to 2.4)	1.6 (0.9 to 2.4)	<0.001
Opioids and cocaine	1.2 (0.6 to 2.0)	1.1 (0.5 to 1.9)	1.1 (0.5 to 1.9)	1.1 (0.5 to 1.9)	1.1 (0.5 to 1.8)	1.1 (0.5 to 1.8)	1.1 (0.5 to 1.8)	1.1 (0.5 to 1.8)	2.0 (1.2 to 3.0)	2.0 (1.2 to 3.0)	2.0 (1.2 to 3.0)	2.0 (1.2 to 3.0)	2.0 (1.2 to 3.0)	2.0 (1.2 to 3.0)	2.0 (1.2 to 3.0)	2.0 (1.2 to 3.0)	2.0 (1.2 to 3.0)	2.0 (1.2 to 3.0)	2.0 (1.2 to 3.0)	2.0 (1.2 to 3.0)	2.0 (1.2 to 3.0)	2.0 (1.2 to 3.0)	0.02
Opioids and methamphetamine	1.2 (0.6 to 2.0)	-	1.1 (0.5 to 1.9)	1.1 (0.5 to 1.9)	1.1 (0.5 to 1.8)	1.1 (0.5 to 1.8)	1.1 (0.5 to 1.8)	1.1 (0.5 to 1.8)	1.0 (0.5 to 1.8)	1.0 (0.5 to 1.8)	1.0 (0.5 to 1.8)	1.0 (0.5 to 1.8)	1.0 (0.5 to 1.8)	1.0 (0.5 to 1.8)	1.0 (0.5 to 1.8)	1.0 (0.5 to 1.8)	1.0 (0.5 to 1.8)	1.0 (0.5 to 1.8)	1.0 (0.5 to 1.8)	1.0 (0.5 to 1.8)	1.0 (0.5 to 1.8)	1.0 (0.5 to 1.8)	0.02
Population count	861616	894847	908091	923139	936058	950364	962478	973968	983440	992853	1000984	1006858	1022990	1035910	1048300	1060747	1072179	1083032	1092738	1102570	1112108		

\*Opioids and cocaine (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T40.9); Opioids and benzodiazepines (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T40.9); Opioids and alcohol (underlying: R18.0, X40-46, X60-65, X85, Y10-Y15; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T51.0, T51.1, T51.9); \*Opioids and methamphetamine (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T43.6); †Non-parametric Jonckheere-Terpstra test for trend.





**Figure 3** Trends in opioid death rates among US non-Hispanic American Indian/Alaska Native 12 and older by individual opioid types\*. \*Heroin (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.1); natural and semi-synthetic (prescription) opioids (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.2); methadone (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.3); synthetic opioids other than methadone (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.4).

opioids in combination with psychostimulants from 2015 to 2017.<sup>16</sup> Aside from the elevated risk of overdose, the co-use of opioids with other substances has been shown to negatively impact treatment outcomes,<sup>21</sup> including lower rates of treatment retention.<sup>22</sup> Similarly, co-use of alcohol with other substances has been associated with increased relapse rates.<sup>23</sup> Given the increased risk of overdose and poor treatment outcomes, it is essential that substance use treatment programmes, interventions, and policies consider the complexities surrounding polysubstance use, including identifying and addressing the root causes of such polysubstance use.

Regarding trends in specific opioid types fueling overdose mortality, our finding that AI/AN deaths resulting from synthetic opioids have increased sharply in recent years indicates AI/AN communities have experienced similar drivers of mortality as the general US population. This group of opioids contains illicitly manufactured fentanyl, a highly potent synthetic opioid that can increase the risk of overdose and mortality in unregulated and unknown quantities.<sup>24 25</sup> While we cannot determine from these data whether the fentanyl involved in an overdose was prescribed or unregulated, current evidence points to increased illicit fentanyl poisoning in the USA,<sup>26 27</sup> especially in combination with other drugs, as a key engine of drug poisoning deaths. Numerous analyses indicate a growing role for fentanyl in drug overdose deaths. A study consisting of toxicology data from 10 US states showed that close to 60% of individuals who died of drug overdoses tested positive for fentanyl and fentanyl analogues in addition to cocaine, methamphetamine and heroin.<sup>28</sup> Furthermore, overdose deaths resulting from

fentanyl increased nearly 12-fold from 2013 to 2019.<sup>8</sup> Qualitative and mixed methods studies indicate that illicitly manufactured fentanyl, as opposed to prescription synthetic opioids, drive these trends.<sup>29 30</sup> Our results demonstrate the need for harm reduction interventions to mitigate the dangers of fentanyl, especially among individuals using unregulated drugs (eg, naloxone training and safe drug supplies), along with improved access to evidence-based treatment programmes that offer opioid agonist treatment.<sup>31</sup>

These findings highlight existing inequities in drug-related deaths and may point to broader systemic factors that disproportionately affect members of AI/AN communities. AIs and ANs continue to encounter stressors that stem from diminished socioeconomic prospects, racism and historical trauma from colonisation. These stressors often contribute significantly to the heightened drug use and related overdoses in the AI/AN population.<sup>13 15</sup> Despite this disproportionate burden, Indigenous communities continue to encounter significant challenges in treatment access, availability<sup>32</sup> and quality.<sup>33</sup> A recent study using 2017 and 2018 data showed that only 22% of AI/AN-serving treatment centres offer opioid agonists. Furthermore, they found that only 40% of AI/AN persons in specialty treatment receive medication-assisted treatment for opioid use disorder.<sup>32</sup> To mitigate the impact of drug overdose on AI/AN communities, leverage points for intervention must look at the root causes and structural factors that shape substance use and addiction and seek to expand specialty treatment programmes for AI/AN communities.



**Table 4** Trends in opioid death rates per 100 000 (95% CI) among US non-Hispanic American Indian/Alaska Native 12 and older by individual opioid types\*

	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	Trend p value†	
<b>Overall</b>																							
Heroin	1.2 (0.7 to 1.8)	1.2 (0.8 to 1.8)	1.1 (0.7 to 1.6)	1.1 (0.6 to 1.6)	1.1 (0.6 to 1.7)	1.1 (0.7 to 1.6)	1.0 (0.6 to 1.5)	1.1 (0.7 to 1.5)	1.2 (0.8 to 1.8)	1.2 (0.8 to 1.8)	1.8 (1.2 to 2.4)	1.4 (0.9 to 1.9)	2.1 (1.5 to 2.8)	2.2 (1.6 to 2.8)	3.3 (2.5 to 4.1)	4.4 (3.6 to 5.3)	5.3 (4.4 to 6.3)	5.9 (4.9 to 6.9)	6.1 (5.1 to 7.1)	5.9 (4.9 to 6.9)	6.3 (5.3 to 7.3)	<0.001	
Methadone	1.1 (0.7 to 1.7)	1.1 (0.7 to 1.6)	1.1 (0.7 to 1.6)	1.2 (0.7 to 1.7)	1.6 (1.1 to 2.2)	2.5 (1.8 to 3.2)	2.8 (2.1 to 3.6)	3.0 (2.3 to 3.8)	2.9 (2.2 to 3.7)	3.7 (2.9 to 4.6)	3.7 (2.9 to 4.5)	3.4 (2.6 to 4.2)	3.4 (2.6 to 4.2)	3.3 (2.6 to 4.2)	2.6 (1.9 to 3.3)	2.2 (1.6 to 2.9)	1.8 (1.1 to 2.4)	1.7 (1.2 to 2.2)	2.1 (1.5 to 2.7)	2.1 (1.5 to 2.7)	1.2 (0.8 to 1.7)	1.4 (1.0 to 2.0)	0.70
Natural and semi-synthetic (prescription) opioids	1.4 (0.9 to 2.0)	1.3 (0.8 to 1.9)	1.8 (1.2 to 2.4)	2.1 (1.5 to 2.8)	2.4 (1.8 to 3.1)	2.9 (2.2 to 3.7)	3.1 (2.4 to 3.9)	3.5 (2.7 to 4.4)	4.2 (3.3 to 5.1)	4.6 (3.7 to 5.5)	6.3 (5.3 to 7.5)	6.0 (5.0 to 7.1)	5.6 (4.7 to 6.7)	6.9 (5.8 to 8.0)	6.7 (5.6 to 7.8)	7.4 (6.3 to 8.6)	6.8 (5.8 to 8.0)	6.5 (5.5 to 7.6)	6.6 (5.5 to 7.7)	6.6 (5.5 to 7.7)	4.5 (3.7 to 5.5)	5.1 (4.2 to 6.0)	<0.001
Synthetic opioids (other than methadone)	1.1 (0.7 to 1.7)	1.1 (0.7 to 1.6)	1.1 (0.7 to 1.6)	1.1 (0.6 to 1.6)	1.0 (0.6 to 1.5)	1.2 (0.8 to 1.8)	1.3 (0.9 to 1.8)	1.3 (0.9 to 1.8)	1.1 (0.7 to 1.7)	2.2 (1.6 to 2.9)	2.8 (2.1 to 3.5)	1.6 (1.1 to 2.2)	1.5 (1.0 to 2.1)	1.9 (1.4 to 2.6)	1.5 (1.1 to 2.1)	2.0 (1.5 to 2.7)	2.3 (1.7 to 3.0)	5.1 (4.2 to 6.1)	7.6 (6.5 to 8.8)	8.4 (7.3 to 9.7)	12.5 (11.1 to 14.0)	<0.001	
Population count	1764431	1830341	1857916	1888990	1917057	1946151	1972126	1996129	2016480	2036583	2054468	2067226	2099967	2126296	2151271	2176524	2199588	2222736	2243570	2265155	2285417		
<b>Female</b>																							
Heroin	1.1 (0.5 to 1.9)	1.1 (0.5 to 1.8)	1.1 (0.5 to 1.8)	1.0 (0.5 to 1.6)	1.0 (0.5 to 1.7)	1.0 (0.5 to 1.7)	1.0 (0.5 to 1.7)	1.0 (0.5 to 1.7)	1.0 (0.5 to 1.7)	1.0 (0.5 to 1.6)	0.9 (0.5 to 1.6)	1.0 (0.5 to 1.7)	1.7 (1.0 to 2.5)	1.7 (1.0 to 2.6)	1.8 (1.1 to 2.7)	2.2 (1.4 to 3.2)	2.8 (1.9 to 3.9)	3.9 (2.8 to 5.1)	4.2 (3.1 to 5.4)	4.2 (3.1 to 5.4)	3.1 (2.2 to 4.2)	4.9 (3.7 to 6.2)	0.056
Methadone	1.1 (0.5 to 1.9)	1.1 (0.5 to 1.8)	1.1 (0.5 to 1.8)	1.2 (0.6 to 2.0)	1.7 (1.1 to 2.6)	1.6 (0.9 to 2.5)	2.2 (1.4 to 3.4)	2.3 (1.5 to 3.4)	2.7 (1.8 to 3.8)	3.0 (2.0 to 4.1)	2.2 (1.4 to 3.2)	3.5 (2.5 to 4.7)	3.5 (2.5 to 4.7)	3.6 (2.6 to 4.6)	2.6 (1.7 to 3.6)	1.5 (0.9 to 2.1)	1.3 (0.7 to 2.2)	1.4 (0.8 to 2.2)	1.7 (1.1 to 2.6)	1.7 (1.1 to 2.6)	1.4 (0.8 to 2.1)	1.4 (0.8 to 2.2)	0.32
Natural and semi-synthetic (prescription) opioids	1.1 (0.5 to 1.9)	1.1 (0.5 to 1.8)	2.0 (1.2 to 3.0)	1.4 (0.8 to 2.3)	1.4 (0.8 to 2.3)	2.3 (1.5 to 3.4)	2.6 (1.7 to 3.7)	2.0 (1.2 to 2.9)	4.6 (3.4 to 6.1)	3.4 (2.3 to 4.6)	5.0 (3.8 to 6.5)	5.2 (3.9 to 6.6)	5.6 (4.3 to 7.1)	6.1 (4.7 to 7.6)	6.7 (5.3 to 8.3)	8.1 (7.1 to 9.1)	5.7 (4.4 to 7.1)	6.2 (4.9 to 7.8)	6.0 (4.7 to 7.5)	4.6 (3.4 to 5.9)	4.8 (3.6 to 6.1)	<0.001	
Synthetic opioids (other than methadone)	1.1 (0.5 to 1.9)	1.1 (0.5 to 1.8)	1.1 (0.5 to 1.8)	1.0 (0.5 to 1.6)	1.0 (0.5 to 1.7)	1.3 (0.7 to 2.1)	1.3 (0.7 to 2.1)	1.3 (0.7 to 2.1)	1.1 (0.5 to 1.8)	2.2 (1.4 to 3.0)	2.2 (1.4 to 3.2)	2.0 (1.2 to 2.9)	1.5 (0.8 to 2.3)	2.1 (1.3 to 3.1)	1.5 (0.9 to 2.4)	1.5 (0.9 to 2.3)	1.9 (1.2 to 2.7)	3.9 (2.9 to 5.2)	4.9 (3.7 to 6.2)	5.3 (4.1 to 6.7)	8.6 (7.0 to 10.4)	<0.001	
Population count	902815	935494	949825	965851	980999	995787	1009648	1022161	1033040	1043730	1053484	1060368	1076977	1090386	1102971	1115777	1127409	1139704	1150832	1162565	1173309		
<b>Male</b>																							
Heroin	1.3 (0.6 to 2.1)	1.3 (0.7 to 2.2)	1.1 (0.5 to 1.9)	1.1 (0.5 to 1.9)	1.4 (0.7 to 2.2)	1.3 (0.7 to 2.1)	1.0 (0.5 to 1.8)	1.1 (0.6 to 1.9)	1.5 (0.9 to 2.4)	1.5 (0.8 to 2.4)	2.6 (1.7 to 3.7)	1.7 (1.0 to 2.6)	2.5 (1.7 to 3.6)	3.5 (2.4 to 4.7)	4.8 (3.5 to 6.2)	6.7 (5.2 to 8.3)	7.9 (6.3 to 9.7)	8.0 (6.4 to 9.8)	8.1 (6.5 to 9.8)	8.8 (7.1 to 10.6)	7.7 (6.2 to 9.5)	<0.001	
Methadone	1.2 (0.6 to 2.0)	1.1 (0.5 to 1.9)	1.1 (0.5 to 1.9)	1.1 (0.5 to 1.9)	1.5 (0.8 to 2.4)	3.4 (2.3 to 4.6)	3.4 (2.4 to 4.7)	3.6 (2.5 to 4.9)	3.1 (2.1 to 4.2)	4.4 (3.2 to 5.8)	5.2 (3.9 to 6.7)	3.3 (2.3 to 4.5)	4.2 (3.0 to 5.5)	4.2 (3.0 to 5.7)	2.6 (1.7 to 3.7)	1.9 (1.2 to 2.8)	2.3 (1.4 to 3.3)	1.9 (1.2 to 2.9)	2.5 (1.6 to 3.5)	1.9 (1.2 to 2.9)	1.0 (0.5 to 1.7)	>0.99	
Natural and semi-synthetic (prescription) opioids	1.6 (0.9 to 2.6)	1.6 (0.9 to 2.5)	2.8 (1.8 to 4.0)	2.0 (1.2 to 3.6)	2.5 (1.6 to 3.6)	3.6 (2.5 to 4.9)	3.6 (2.5 to 4.9)	5.1 (3.8 to 6.7)	3.7 (2.6 to 4.9)	5.8 (4.4 to 7.4)	7.7 (6.1 to 9.5)	6.9 (5.3 to 8.6)	5.7 (4.3 to 7.2)	7.7 (6.1 to 9.5)	6.7 (5.2 to 8.3)	8.3 (6.7 to 10.1)	8.6 (7.0 to 10.6)	8.5 (6.9 to 10.1)	7.1 (5.6 to 8.6)	4.5 (3.4 to 5.9)	5.4 (4.1 to 6.8)	<0.001	
Synthetic opioids (other than methadone)	1.2 (0.6 to 2.0)	1.1 (0.5 to 1.9)	1.1 (0.5 to 1.9)	1.1 (0.5 to 1.9)	1.1 (0.5 to 1.8)	1.5 (0.8 to 2.3)	1.2 (0.6 to 2.0)	1.3 (0.7 to 2.2)	1.2 (0.6 to 2.0)	2.4 (1.5 to 3.5)	3.4 (2.4 to 4.6)	1.2 (0.6 to 2.0)	1.6 (0.9 to 2.4)	1.7 (1.0 to 2.6)	1.5 (0.9 to 2.4)	2.5 (1.7 to 3.6)	2.8 (1.9 to 3.9)	6.3 (4.9 to 7.9)	10.5 (8.7 to 12.5)	11.7 (9.8 to 13.8)	16.5 (14.2 to 19.0)	<0.001	
Population count	861616	894847	908091	923139	936058	950364	962478	973968	983440	992853	1000984	1006858	1022990	1035910	1048300	1060747	1072179	1083032	1092738	1102570	1112108		

\*Methadone (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40-3); synthetic opioids other than methadone (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40-4).

†Heroin (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40-3); natural and semi-synthetic (prescription) opioids (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40-2).

‡Non-parametric Jonckheere-Terpstra test for trend.



Furthermore, sex differences were apparent throughout our results. In our primary and supplemental analysis, male populations tended to experience higher rates and higher increases in drug overdose deaths than female populations. Sex differences observed in drug overdose studies are often characterised by higher rates in men.<sup>34 35</sup> However, historical trends are not uniform, and gaps between male and female populations have narrowed at specific periods during the drug overdose crisis and widened at other points.<sup>35</sup> Our observed results may reflect differential attitudes towards risk and varying social expectations for males and females in AI/AN communities and may suggest the need for targeted gender-sensitive interventions.

Finally, two essential observations in our study may shed light on the critical role of socioeconomic status in overdose deaths. In our supplemental analysis of opioid only deaths, we found that individuals aged 35–44 carried the highest burden of death rates for most of the years from 1999 to 2010. Additionally, among this same age, overdose death rates spiked immediately following 2008. The period between 2008 and 2009 was defined by a worldwide economic crisis characterised by high unemployment rates.<sup>36</sup> Furthermore, most overdose deaths during the same period occurred among individuals who often bear the financial responsibility for their families (ie, 35–44 age group). While additional studies will be needed to ascertain the relationship between the 2008 financial crises and the escalation in drug overdose deaths among AI/AN communities, our findings offer compelling insights into the importance of socioeconomic well-being in the context of substance use. Our findings should be considered within the constraints of certain important limitations. First, to capture as much AI/AN data as possible, age-adjusted results were not obtained because they required suppressing AI/AN-specific results. However, in comparing age-adjusted and raw rates, we found rates to be reasonably similar. Second, subgroup data with small counts were aggregated due to data-use agreement requirements. Third, due to the different demographic reporting techniques between the mortality data from death certificates (reported by surviving next of kin or funeral director observation)<sup>37</sup> and population data from the US Census Bureau (self-reporting), inconsistencies could arise between the two groups, which could translate into biased mortality rates<sup>38 39</sup> across certain demographic groups (especially race and ethnicity). Fourth, deaths with specific demographics reported as ‘not stated’ or unknown were not included in demographic-specific analyses.

On the other hand, our study has some unique strengths worth mentioning. First, this is one of the first studies to investigate AI/AN opioid overdose trends over time across the USA, with emphasis on the drug overdose implications of the concurrent use of opioids with alcohol, benzodiazepines, cocaine or methamphetamine contributes in this population. Second, by stratifying our findings by sex and comparing mortality rates between

NH AI/AN groups, our findings are mainly presented to better identify subpopulations at risk of overdose. Finally, our results highlight the historical trends of opioids overdose mortality among AI/AN populations by specific opioid types, including heroin, natural and semi-synthetic (prescription) opioids (eg, oxycodone, hydrocodone), methadone, and synthetic opioids other than methadone (eg, fentanyl, tramadol)). Providing these distinctions is essential for public health prevention and harm reduction strategies directed towards AI/AN communities.

## CONCLUSIONS

Overall, our results suggest that AI/AN populations continue to face rising levels of overdose mortality due to the use of opioids alone and in combination with other substances, with rates as high or higher than all other racial/ethnic groups. AI/AN men and those aged 25–44 are especially impacted. While the type of opioid driving these trends has changed over the years, many underlying social factors that drive these patterns have not, including inequities in socioeconomic status, persistent effects of historical trauma and inequities in healthcare access and treatment programmes. Interventions for AI/AN populations with substance use disorders will be more impactful if they are comprehensive, culturally centred and address social determinants of health, including socioeconomic factors and racial and ethnic discrimination.

## Author affiliations

<sup>1</sup>Parkinson School of Health Sciences and Public Health, Loyola University Chicago, Chicago, Illinois, USA

<sup>2</sup>Department of Family Medicine and Public Health Sciences, Wayne State University, Detroit, Michigan, USA

<sup>3</sup>Department of Family and Preventive Medicine, University of Utah Health, Salt Lake City, Utah, USA

<sup>4</sup>Department of Psychology, University of New Mexico, Albuquerque, New Mexico, USA

<sup>5</sup>Albuquerque Area Southwest Tribal Epidemiology Center (AASTEC), Albuquerque Area Indian Health Service, Albuquerque, New Mexico, USA

**Acknowledgements** We thank the anonymous reviewers whose comments and suggestions helped improve and clarify this manuscript.

**Contributors** FQ, EFM, KV, KE and AD contributed to the concept and study design. BT and FQ contributed to acquisition, curation and analysis of data. FQ, EFM, NAM, BT and AD drafted the manuscript. JH and AH-V worked on formatting tables, figures and references and provided edits to the final draft of the manuscript. All authors critically revised the manuscript for important intellectual content. All authors approved the final version of the manuscript. FQ is the guarantor of the study.

**Funding** This research was partly supported by NIH [Grant Number 5R61DA049382-02].

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Not applicable.

**Ethics approval** Ethical approval was not required for this secondary analysis of publicly available aggregate county-level national data, in which no individual information would be identifiable.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available in a public, open access repository. Data are publicly available at the CDC Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) database. Multiple Cause of Death 1999–2019. Available at: <https://wonder.cdc.gov/wonder/help/mcd.html#>. Accessed 1 December 2021.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

#### ORCID iDs

Fares Qeadan <http://orcid.org/0000-0002-3376-220X>

Benjamin Tingey <http://orcid.org/0000-0003-0620-0858>

Jalene Herron <http://orcid.org/0000-0002-7161-8970>

#### REFERENCES

- Hedegaard H, Miniño AM, Warner M. *Drug overdose deaths in the United States, 1999–2018*, 2020.
- Jalal H, Buchanich JM, Roberts MS, *et al*. Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016. *Science* 2018;361::eaau1184.
- Mack KA, Jones CM, Ballesteros MF. Illicit Drug Use, Illicit Drug Use Disorders, and Drug Overdose Deaths in Metropolitan and Nonmetropolitan Areas - United States. *MMWR Surveill Summ* 2017;66:1–12.
- Centers for Disease Control and Prevention, National Center for Health Statistics. Multiple cause of death 1999–2019 on CDC wonder online database, released in 2020. data are from the multiple cause of death files, 1999–2019, as compiled from data provided by the 57 vital statistics jurisdictions through the vital statistics cooperative program.. Available: <http://wonder.cdc.gov/mcd-icd10.html> [Accessed 02 Apr 2021].
- Tipps RT, Buzzard GT, McDougall JA. The opioid epidemic in Indian country. *J Law Med Ethics* 2018;46:422–36.
- Joshi S, Weiser T, Warren-Mears V. Drug, Opioid-Involved, and Heroin-Involved Overdose Deaths Among American Indians and Alaska Natives - Washington, 1999–2015. *MMWR Morb Mortal Wkly Rep* 2018;67:1384–7.
- Han Y, Yan W, Zheng Y, *et al*. The rising crisis of illicit fentanyl use, overdose, and potential therapeutic strategies. *Transl Psychiatry* 2019;9:282.
- Mattson CL, Tanz LJ, Quinn K, *et al*. Trends and geographic patterns in drug and synthetic opioid overdose deaths - United States, 2013–2019. *MMWR Morb Mortal Wkly Rep* 2021;70:202–7.
- Wilson N, Kariisa M, Seth P, *et al*. Drug and opioid-involved overdose deaths - United States, 2017–2018. *MMWR Morb Mortal Wkly Rep* 2020;69:290–7.
- Compton WM, Valentino RJ, DuPont RL. Polysubstance use in the U.S. opioid crisis. *Mol Psychiatry* 2021;26:41–50.
- Jones CM, Underwood N, Compton WM. Increases in methamphetamine use among heroin treatment admissions in the United States, 2008–17. *Addiction* 2020;115:347–53.
- Brave Heart MYH. The historical trauma response among natives and its relationship with substance abuse: a Lakota illustration. *J Psychoactive Drugs* 2003;35:7–13.
- Whitesell NR, Beals J, Crow CB, *et al*. Epidemiology and etiology of substance use among American Indians and Alaska natives: risk, protection, and implications for prevention. *Am J Drug Alcohol Abuse* 2012;38:376–82.
- Paradies Y. Colonisation, racism and Indigenous health. *J Popul Res* 2016;33:83–96.
- Skewes MC, Blume AW. Understanding the link between racial trauma and substance use among American Indians. *Am Psychol* 2019;74:88–100.
- Kariisa M, Scholl L, Wilson N, *et al*. Drug Overdose Deaths Involving Cocaine and Psychostimulants with Abuse Potential - United States, 2003–2017. *MMWR Morb Mortal Wkly Rep* 2019;68:388–95.
- CDC/NCHS. National vital statistics system, mortality. trends in deaths rates. Available: <https://www.cdc.gov/drugoverdose/data/analysis.html>
- White JM, Irvine RJ. Mechanisms of fatal opioid overdose. *Addiction* 1999;94:961–72.
- Vella-Brincat J, Macleod AD. Adverse effects of opioids on the central nervous systems of palliative care patients. *J Pain Palliat Care Pharmacother* 2007;21:15–25.
- Meacham MC, Strathdee SA, Rangel G, *et al*. Prevalence and correlates of Heroin-Methamphetamine Co-Injection among persons who inject drugs in San Diego, California, and Tijuana, Baja California, Mexico. *J Stud Alcohol Drugs* 2016;77:774–81.
- Wang L, Min JE, Krebs E, *et al*. Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users. *Int J Drug Policy* 2017;49:32–40.
- Williamson A, Darke S, Ross J, *et al*. The effect of persistence of cocaine use on 12-month outcomes for the treatment of heroin dependence. *Drug Alcohol Depend* 2006;81:293–300.
- Staiger PK, Richardson B, Long CM, *et al*. Overlooked and underestimated? problematic alcohol use in clients recovering from drug dependence. *Addiction* 2013;108:1188–93.
- Volpe DA, McMahan Tobin GA, Mellon RD, *et al*. Uniform assessment and ranking of opioid  $\mu$  receptor binding constants for selected opioid drugs. *Regul Toxicol Pharmacol* 2011;59:385–90.
- Centers for Disease Control and Prevention. Other drugs. fentanyl contamination of other drugs is increasing overdose risk. Available: <https://www.cdc.gov/drugoverdose/data/otherdrugs.html> [Accessed 09 Apr 2021].
- O'Donnell J, Gladden RM, Goldberger BA, *et al*. Notes from the Field: Opioid-Involved Overdose Deaths with Fentanyl or Fentanyl Analogs Detected - 28 States and the District of Columbia, July 2016–December 2018. *MMWR Morb Mortal Wkly Rep* 2020;69:271–3.
- Rudd RA, Aleshire N, Zibbell JE, *et al*. Increases in Drug and Opioid Overdose Deaths--United States, 2000–2014. *MMWR Morb Mortal Wkly Rep* 2016;64:1378–82.
- O'Donnell JK, Halpin J, Mattson CL, *et al*. Deaths Involving Fentanyl, Fentanyl Analogs, and U-47700 - 10 States, July–December 2016. *MMWR Morb Mortal Wkly Rep* 2017;66:1197–202.
- Carroll JJ, Marshall BDL, Rich JD, *et al*. Exposure to fentanyl-contaminated heroin and overdose risk among illicit opioid users in Rhode island: a mixed methods study. *Int J Drug Policy* 2017;46:136–45.
- Ciccarone D, Ondocsin J, Mars SG. Heroin uncertainties: Exploring users' perceptions of fentanyl-adulterated and -substituted 'heroin'. *International Journal of Drug Policy* 2017;46:146–55.
- Centers for Disease Control and Prevention. Fentanyl. What is fentanyl? Available: <https://www.cdc.gov/drugoverdose/opioids/fentanyl.html> [Accessed 09 Apr 2021].
- Krawczyk N, Garrett B, Ahmad NJ, *et al*. Medications for opioid use disorder among American Indians and Alaska natives: availability and use across a national sample. *Drug Alcohol Depend* 2021;220:108512.
- Legha R, Raleigh-Cohn A, Fickenscher A, *et al*. Challenges to providing quality substance abuse treatment services for American Indian and Alaska native communities: perspectives of staff from 18 treatment centers. *BMC Psychiatry* 2014;14:181
- State Health Facts. Opioid overdose deaths by gender, 2018. Kaiser family Foundation. Available: <https://www.kff.org/other/state-indicator/opioid-overdose-deaths-by-sex/>
- Ho JY. Cycles of gender convergence and divergence in drug overdose mortality. *Popul Dev Rev* 2020;46:443–70.
- Hurd MD, Rohwedder S. Effects of the financial crisis and great recession on American households, 2010. National Bureau of economic research. Available: <https://www.nber.org/papers/w16407>
- CDC WONDER. Multiple Cause of Death 1999 - 2019, 2021. Available: <https://wondercdc.gov/wonder/help/mcdhtml#>. [Accessed 01 Dec 2021].
- Arias E, Schauman WS, Eschbach K, *et al*. The validity of race and Hispanic origin reporting on death certificates in the United States. *Vital Health Stat 2* 2008;1–23.
- Rosenberg HM, Maurer JD, Sorlie PD, *et al*. Quality of death rates by race and Hispanic origin: a summary of current research, 1999. *Vital Health Stat 2* 1999:1–13.